AmacaThera raises $3.25 mln for post-op pain therapy

AmacaThera, a Toronto-based developer of injectable hydrogel technology for medical applications, has raised $3.25 million in initial seed-stage financing.

The round was led by BioVentures and Viva Biotech and joined by Grey Sky Venture Partners and other investors.

Based on research discovered at the University of Toronto, AmacaThera’s technology aims to provide a sustained release of therapeutic agents from injectable, biocompatible hydrogels.

Its first product, AMT-143, targets post-operative pain control with the goal of eliminating opioid use.

AmacaThera will use the funds raised for Phase I clinical trials.


New opioid-alternative raises $3.25 million for Phase I trials

TORONTO, Jan. 11, 2019 /PRNewswire/ — AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has already raised $3.25 million (CAD) in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners and welcomes additional investors.

AmacaThera’s founding technology was discovered at the University of Toronto by Dr. Molly Shoichet, a leading expert on polymer design and recent winner of the prestigious Killam Prize in Engineering. One of the key scientists involved in this research, Dr. Mike Cooke, will serve as the CEO of the new company.

AmacaThera envisions their proprietary technology to allow sustained and controllable release of diverse therapeutic agents from injectable, biocompatible hydrogels. Their first product, AMT-143, targets superior post-operative pain control with the goal of eliminating opioid use following surgery. The funding raised in this round will be used to advance AmacaThera’s drug delivery platform technology through Phase I clinical proof-of-concept.

AmacaThera is excited about the initial close and is currently in discussions with additional investors and angels for a second closing, which is anticipated in the coming months. Interested investors should contact Mike Cooke (

AmacaThera’s financing round was co-led by Sprout BioVentures and Viva Biotech. Venture partner Mike Serrano-Wu shared his excitement to work with AmacaThera: “We jumped at the chance to work with Molly and Mike and break open the field of hydrogel-encapsulated therapeutics. The unique inverse thermal gelling property of AMT-143 will lead to multiple opportunities for the AmacaThera platform to significantly improve patient care.”

Grey Sky Venture Partners have also joined the seed round. Todd McIntyre, partner at Grey Sky Venture Partners said: “Grey Sky is very pleased to work with the AmacaThera team to bring AMT-143 to market. There is a large unmet need for a non-opioid pain control following surgery, and AmacaThera’s technology provides a unique solution to the sustained release of acute pain medications.”

AmacaThera was nurtured in Dr. Shoichet’s laboratory with assistance from numerous accelerators, including the Creative Destruction Lab at the Rotman School of Management, University of Toronto Early-Stage Technology, the Ontario Biosciences Innovation Organization, MaRS Innovation, and the U of T Innovations & Partnership Office.

About Sprout BioVentures and Viva Biotech

Sprout BioVentures and Viva Biotech are each focused on propelling high-potential companies from idea to value creation. With a particular emphasis on seed-stage investments, Sprout and Viva leverage proprietary technology and nimble incubator resources to efficiently de-risk drug discovery efforts. More information is available at and

About Grey Sky Venture Partners

Grey Sky Venture Partners is an early-stage investment fund providing capital and intellectual property to passionate entrepreneurs building innovative, next-generation life sciences companies that will create an impact in the complex and rapidly changing healthcare system. More information is available at